Emalex Biosciences

Series-B
emalexbiosciences.com Biotech & Healthcare Chicago, United States Founded 2018 51–100 employees
Total Funding $285M
Latest Round $250M Series-B
Last Announced Nov 3, 2022
Investors 5 Backers
Decision Makers 5 Available

About Emalex Biosciences

Emalex Biosciences is a biotech startup that develops new treatments for central nervous system disorders.

Company Details

Intelligence Dossier

Corporate & Operational Profile

Primary Industry Biotech & Healthcare
Funding Stage Series-B
Global Headquarters Chicago, United States
Year Founded 2018
Team Size 51–100 employees
Tracked Since Nov 8, 2026

Web & Domain Identity

Official Website emalexbiosciences.com
Domain Registered Date Undisclosed

Social & Network Presence

X / Twitter Profile @ParagonBiosci
LinkedIn Corporate Company Profile

Company Milestones & Timeline

3 Events
  1. Capital Raise

    Raised $250,000,000 · Series-B

    Backed by Bain Capital Life Sciences

  2. Capital Raise

    Raised $35,000,000 · Series-B

    Backed by Paragon Biosciences

  3. Milestone

    Company founded

    Chicago, United States

Investors & Backers

5
Bain Capital Life Sciences
Lead
Paragon Biosciences
Lead
Fidelity
Horizon Technology Finance
Valor Equity Partners

Funding History

2 Rounds
Series-B equity · Nov 3, 2022

Round backers: Bain Capital Life Sciences

Series-B equity · Mar 23, 2021

Round backers: Paragon Biosciences

$35,000,000 finsmes.com

Founders & Leadership

3

Atul Mahableshwarkar

Chief Medical Officer

Work email & phone locked Unlock →

Jeff Aronin

Founder

Work email & phone locked Unlock →

Timothy Rudolphi

Chief Commercial Officer

Work email & phone locked Unlock →

Press Coverage & Sources

Recently Funded Biotech & Healthcare Startups

View all

Search the startup feeds free with 50 starter credits.

Recently funded startups
New SaaS launches
Never pay twice for contacts